Marcus Boehm Biography and Net Worth

Mr. Marcus Boehm is the Director of Vyant Bio.

What is Marcus Boehm's net worth?: The estimated net worth of Marcus Boehm is at least $19,192.23 as of May 28th, 2021. Mr. Boehm owns 98,929 shares of Vyant Bio stock worth more than $19,192 as of April 26th. This net worth evaluation does not reflect any other assets that Mr. Boehm may own. Learn More about Marcus Boehm's net worth.
How do I contact Marcus Boehm?: The corporate mailing address for Mr. Boehm and other Vyant Bio executives is 2370 State Route 70 Suite 310, Cherry Hill NJ, 08002. Vyant Bio can also be reached via phone at (201) 479-1357 and via email at [email protected]. Learn More on Marcus Boehm's contact information.
Has Marcus Boehm been buying or selling shares of Vyant Bio?: Marcus Boehm has not been actively trading shares of Vyant Bio during the past quarter. Most recently, on Monday, December 6th, Marcus Boehm bought 5,000 shares of Vyant Bio stock. The stock was acquired at an average cost of $1.69 per share, with a total value of $8,450.00. Learn More on Marcus Boehm's trading history.
Who are Vyant Bio's active insiders?: Vyant Bio's insider roster includes Marcus Boehm (Director), R. Fletcher (Director), Paul Hansen (Director), John Roberts (CEO), and Yung-Ping Yeh (Insider). Learn More on Vyant Bio's active insiders.

Marcus Boehm Insider Trading History at Vyant Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/6/2021	Buy	5,000	$1.69	$8,450.00
10/27/2021	Buy	5,000	$2.10	$10,500.00
9/29/2021	Buy	5,000	$2.44	$12,200.00
8/25/2021	Buy	5,000	$2.58	$12,900.00
7/28/2021	Buy	5,000	$2.92	$14,600.00
5/28/2021	Buy	5,000	$3.68	$18,400.00	98,929

Marcus Boehm Buying and Selling Activity at Vyant Bio

Vyant Bio Company Overview

Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). The company is based in Cherry Hill, New Jersey.

Today's Range

Now: $0.19

$0.18

$0.20

50 Day Range

MA: $0.19

$0.19

2 Week Range

Now: $0.19

$0.14

$1.58

Volume

19,100 shs

Average Volume

161,822 shs

Market Capitalization

$1.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.73

The "Smart Money" Is Ready for May 1st Are You?

From Stansberry Research | Ad

Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.

One Former Wall St. Trader Explains Why…